infarction

Felix Zijlstra Felix Zijlstra, University Medical Center Groningen, The Netherlands Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits,

Warren Cantor Tony Gershlick REFERENCE: Abstract 2404-3 SCAI-ACCi2 Late-Breaking Clinical Trials II: Acute Myocardial Infarction Warren Cantor, University of Toronto COMMENT: Tony Gershlick, Leicester

Curt Diehm REFERENCE: European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria CURT DIEHM, University of Heidelberg Peripheral arterial disease (PAD) can be diagnosed easily by a

Soko Setoguchi Douglas Zipes SOKO SETOGUCHI, Brigham And Women’s Hospital, Boston COMMENT: DOUGLAS ZIPES, University of Indiana, Indianapolis REFERENCE: Abstract 1018-148, American College of Ca

Judith Hochman Timothy Gardner Girish Mood Marc Cohen Late Opening of Total Occlusion: No Benefit from PCI for Patients with STEMI REFERENCE: LBCT II News Conference November 14th 2006 JUDITH HOCHMAN,

Shamir Mehta Keith Fox Petr Widimsky Gerrit Veen OASIS 5 & 6: Fondaparinux Anticoagulation: Benefit on Mortality, Events and Bleeding in Acute Coronary Syndromes and ST-Elevation Myocardial Infarc

Vivek Rajagopal, The Cleveland Clinic Foundation, OH American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta. Abstract Number: 973-234 Patients admitted with ST-elevation a

Peter Smith, Duke University Medical Center, Durham, NC Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006 The drug pexelizumab, targeting inflammation, reduced the risk of death

Frans Van de Werf, University of Leuven Abstract Lancet 367:569-578 Results from a new study just published in the Lancet look into the role of facilitated PCI in patients with ST-elevation acute myoc

Anthony H. Gershlick, Leicester University Abstract: N Engl J Med 2005; 353:2758 If your patient with myocardial infarction has been treated with thrombolysis as primary therapy, and if reperfusion is

Primary angioplasty after a myocardial infarction is also better than thrombolysis in a real world setting: though up to two hours after the infarction the two methods are equivalent, according to Swe

Gunnar Gislason As the dust continues to settle on the Vioxx issue, there is naturally a desire to look further at potential cardiovascular risks associated with COX-2 inhibitors and, indeed, other no